CRL

AI Memo

Charles River Laboratories International

As of 2026-07-29/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-07-29 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

—

Key catalyst

Q2 2026 earnings and guidance check • 2026-08-05

Expected move: +7%

Biggest risk

Q1 showed a 1.5% organic revenue decline, lower non-GAAP operating margin, and 12% lower non-GAAP EPS, with pressure from DSA study costs, RMS mix, and executive-transition stock compensation [#SEC-8K-2026-05-07]. A Q2 miss or guidance reduction would challenge the recovery thesis.

Invalidation

Break below $205 or thesis failure.

What would change my mind?

Q2 could validate improving DSA demand and support a recovery in organic growth and margins. Portfolio refocusing, TuneLab, and NGS collaborations provide credible strategic optionality, but the latter two are not yet proven earnings drivers.

Research note

Recommendation

—

Confidence

medium

As of

2026-07-29

Base target

$250

p=50%

Bull target

$270

p=25%

Bear target

$205

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Portfolio simplification and margin proof
Lilly TuneLab collaboration
NGS and advanced-therapy service adoption

BearKey bullets

A reported $16.9 million open-market director sale is a secondary sentiment risk, not evidence about operating performance [#SEC-FORM4-2026-07-01].
Divestiture-related revenue loss, transition costs, or weaker portfolio execution could offset simplification benefits.
Q2 results may fail to show the expected improvement in organic growth, DSA demand, or margins.

WatchKey bullets

Q2 2026 earnings and guidance check

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $250 (p=50%)

Bull/Bear spread: +15% / -12%

Vs latest close: Bull +15% · Base +7% · Bear -12%

Scenario probabilities

Bull Target: $270 (p=25%)Base Target: $250 (p=50%)Bear Target: $205 (p=25%)

Commentary

News tone is modestly positive from recent NGS and AI/ML collaboration coverage, but the most decision-relevant operating evidence remains the mixed Q1 print and reaffirmed guidance. Q2 earnings are scheduled for August 5; consensus surprise data, analyst revisions, options, short interest, Glassdoor, and sufficient social sentiment are unavailable. This supports a constructive monitoring view rather than a high-conviction rerating call.

As of 2026-07-29 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Portfolio simplification and margin proof
Lilly TuneLab collaboration
NGS and advanced-therapy service adoption

Scenarios

Bull Target (Scenario probability)

$270 / p=25% prob

Base Target (Scenario probability)

$250 / p=50% prob

Bear Target (Scenario probability)

$205 / p=25% prob

Price $234 as of 2026-08-04

Nearest Scenario: Base (∆ 7%)

Targets vs latest close: Bull +15% · Base +7% · Bear -12%

Sentiment & Exposure

News Sentiment (30d)

0.20

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-08-05
Q2 2026 earnings and guidance check
Charles River is scheduled to report Q2 results on August 5. The key test is whether solid DSA bookings and demand tracking cited in Q1 convert into improving organic growth and margins; Q1 revenue was $995.8 million, organic revenue declined 1.5%, and non-GAAP EPS fell 12% while 2026 guidance was reaffirmed [#IR-2026-07-15] [#SEC-8K-2026-05-07].
Prob 55.00% • Move 5.00% • Priced-in 65.00%

Short-term Catalysts

Next few weeks

Portfolio simplification and margin proof
2026-09-30
The CDMO and Cell Solutions divestiture was completed, simplifying the portfolio. The near-term catalyst is evidence that the refocused business can improve margins without an outsized revenue or execution drag [#SEC-8K-2026-05-07].
Prob 55% • Move 7% • Priced-in 55%

Long-term Catalysts

Months to a year

Lilly TuneLab collaboration
2026-12-31
The TuneLab collaboration adds Charles River nonclinical testing expertise to an AI/ML drug-discovery ecosystem and could deepen client relationships, but financial contribution remains unproven [#IR-2026-06-18].
Prob 45% • Move 8% • Priced-in 30%
NGS and advanced-therapy service adoption
2027-03-31
The Arovella collaboration demonstrates commercial use of Charles River GMP NGS and viral-safety testing in cell-therapy development. It supports strategic positioning, but one collaboration is not evidence of a material near-term revenue inflection [#IR-2026-07-13].
Prob 45% • Move 6% • Priced-in 20%

Risks

A reported $16.9 million open-market director sale is a secondary sentiment risk, not evidence about operating performance [#SEC-FORM4-2026-07-01].
Divestiture-related revenue loss, transition costs, or weaker portfolio execution could offset simplification benefits.
Q2 results may fail to show the expected improvement in organic growth, DSA demand, or margins.
RMS mix, DSA study-related costs, and executive-transition compensation could continue to pressure profitability [#SEC-8K-2026-05-07].
TuneLab and NGS collaborations may remain strategically relevant but financially immaterial in the near term.

Peers

Symbol	Summary
LH	More direct operating comparator because Labcorp has drug-development and preclinical CRO exposure overlapping with Charles River’s DSA demand, although diagnostics makes the mix less clean.
IQV	Useful strategic and transaction read-through for discovery services, NAMs, and AI-enabled capabilities, though its larger clinical and data-services mix reduces comparability.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-07-29

AI Stock Memo: CRL - Charles River Laboratories International - RankAlpha